Targeting fibrosis: Mechanisms and clinical trials
M Zhao, L Wang, M Wang, S Zhou, Y Lu… - Signal transduction and …, 2022 - nature.com
Fibrosis is characterized by the excessive extracellular matrix deposition due to
dysregulated wound and connective tissue repair response. Multiple organs can develop …
dysregulated wound and connective tissue repair response. Multiple organs can develop …
The genetics of obesity: from discovery to biology
The prevalence of obesity has tripled over the past four decades, imposing an enormous
burden on people's health. Polygenic (or common) obesity and rare, severe, early-onset …
burden on people's health. Polygenic (or common) obesity and rare, severe, early-onset …
[PDF][PDF] 中国2 型糖尿病防治指南(2013 年版)
翁建平 - 中华糖尿病杂志, 2014 - meditool.cn
随着经济高速发展和工业化进程的加速, 生活方式的改变和老龄化进程的加速,
使我国糖尿病的患病率正呈快速上升的趋势, 成为继心脑血管疾病, 肿瘤之后另一个严重危害 …
使我国糖尿病的患病率正呈快速上升的趋势, 成为继心脑血管疾病, 肿瘤之后另一个严重危害 …
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
JR Ussher, DJ Drucker - Nature Reviews Cardiology, 2023 - nature.com
Type 2 diabetes mellitus (T2DM) and obesity are metabolic disorders characterized by
excess cardiovascular risk. Glucagon-like peptide 1 (GLP1) receptor (GLP1R) agonists …
excess cardiovascular risk. Glucagon-like peptide 1 (GLP1) receptor (GLP1R) agonists …
Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
Aims/hypothesis Tirzepatide is a novel dual glucose-dependent insulinotropic peptide (GIP)
and glucagon-like peptide-1 receptor agonist (GLP-1 RA) currently under review for …
and glucagon-like peptide-1 receptor agonist (GLP-1 RA) currently under review for …
Signaling pathways in obesity: mechanisms and therapeutic interventions
X Wen, B Zhang, B Wu, H Xiao, Z Li, R Li… - Signal transduction and …, 2022 - nature.com
Obesity is a complex, chronic disease and global public health challenge. Characterized by
excessive fat accumulation in the body, obesity sharply increases the risk of several …
excessive fat accumulation in the body, obesity sharply increases the risk of several …
US FDA approved drugs from 2015–June 2020: a perspective
In the present work, we report compilation and analysis of 245 drugs, including small and
macromolecules approved by the US FDA from 2015 until June 2020. Nearly 29% of the …
macromolecules approved by the US FDA from 2015 until June 2020. Nearly 29% of the …
Antidiabetic phytochemicals from medicinal plants: prospective candidates for new drug discovery and development
S Alam, MMR Sarker, TN Sultana… - Frontiers in …, 2022 - frontiersin.org
Diabetes, a chronic physiological dysfunction affecting people of different age groups and
severely impairs the harmony of peoples' normal life worldwide. Despite the availability of …
severely impairs the harmony of peoples' normal life worldwide. Despite the availability of …
[HTML][HTML] Glucagon-like peptide 1 (GLP-1)
TD Müller, B Finan, SR Bloom, D D'Alessio… - Molecular …, 2019 - Elsevier
Background The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular …
Summary Background Glucagon-like peptide-1 (GLP-1) receptor agonists differ in their
structure and duration of action and have been studied in trials of varying sizes and with …
structure and duration of action and have been studied in trials of varying sizes and with …